Marpai (MRAI) Competitors $1.35 -0.03 (-2.17%) As of 07/3/2025 12:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock MRAI vs. NAKA, KDLY, QIPT, ATPC, OPGN, PIII, BDSX, BNR, BMGL, and CCMShould you be buying Marpai stock or one of its competitors? The main competitors of Marpai include KindlyMD (NAKA), Kindly MD (KDLY), Quipt Home Medical (QIPT), Agape ATP (ATPC), OpGen (OPGN), P3 Health Partners (PIII), Biodesix (BDSX), Burning Rock Biotech (BNR), Basel Medical Group (BMGL), and Concord Medical Services (CCM). These companies are all part of the "healthcare" industry. Marpai vs. Its Competitors KindlyMD Kindly MD Quipt Home Medical Agape ATP OpGen P3 Health Partners Biodesix Burning Rock Biotech Basel Medical Group Concord Medical Services Marpai (NASDAQ:MRAI) and KindlyMD (NASDAQ:NAKA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Does the media prefer MRAI or NAKA? In the previous week, Marpai's average media sentiment score of 0.00 equaled KindlyMD'saverage media sentiment score. Company Overall Sentiment Marpai Neutral KindlyMD Neutral Do institutionals & insiders have more ownership in MRAI or NAKA? 49.8% of Marpai shares are owned by institutional investors. 61.3% of Marpai shares are owned by company insiders. Comparatively, 50.5% of KindlyMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, MRAI or NAKA? KindlyMD has lower revenue, but higher earnings than Marpai. KindlyMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarpai$34.87M0.64-$28.75M-$1.82-0.74KindlyMD$2.47M31.12-$3.62M-$0.77-16.56 Which has more volatility & risk, MRAI or NAKA? Marpai has a beta of 4.79, meaning that its stock price is 379% more volatile than the S&P 500. Comparatively, KindlyMD has a beta of 35.16, meaning that its stock price is 3,416% more volatile than the S&P 500. Is MRAI or NAKA more profitable? Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -177.01%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity.Company Net Margins Return on Equity Return on Assets Marpai-85.70% N/A -100.23% KindlyMD -177.01%-146.26%-109.19% SummaryMarpai beats KindlyMD on 7 of the 11 factors compared between the two stocks. Get Marpai News Delivered to You Automatically Sign up to receive the latest news and ratings for MRAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRAI vs. The Competition Export to ExcelMetricMarpaihealth & allied services, not elsewhere classified IndustryBusiness SectorNASDAQ ExchangeMarket Cap$22.32M$124.94M$13.06B$9.02BDividend YieldN/AN/A2.56%4.10%P/E Ratio-0.511.1328.8620.29Price / Sales0.640.5642.42112.84Price / CashN/A2.8025.6857.47Price / Book-0.780.236.285.68Net Income-$28.75M$43.11M$188.91M$249.04M7 Day PerformanceN/A-2.22%3.56%3.30%1 Month PerformanceN/A30.00%4.15%5.20%1 Year Performance87.47%59.16%27.98%21.37% Marpai Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRAIMarpaiN/A$1.35-2.2%N/A+87.5%$22.32M$34.87M-0.51150Gap UpNAKAKindlyMDN/A$13.61-1.7%N/AN/A$83.48M$2.72M-17.68N/APositive NewsKDLYKindly MDN/A$13.85-3.0%N/A+433.3%$83.38M$2.47M-17.98N/APositive NewsQIPTQuipt Home Medical2.4317 of 5 stars$1.75-2.2%$2.85+62.9%-41.6%$77.76M$245.91M-8.331,200ATPCAgape ATP0.0631 of 5 stars$1.33+0.8%N/A-66.5%$66.01M$1.32M-2.2240Gap DownOPGNOpGenN/A$4.76-0.4%N/A+80.5%$47.92M$2.67M0.00100Upcoming EarningsGap DownPIIIP3 Health Partners2.9585 of 5 stars$6.34+0.6%$16.25+156.3%-74.4%$45.28M$1.50B-0.13500Gap DownBDSXBiodesix3.4059 of 5 stars$0.29+1.7%$1.75+509.8%-82.8%$41.36M$71.32M-0.99220Gap UpBNRBurning Rock BiotechN/A$3.20+1.3%N/A-44.8%$34.01M$70.67M-1.691,390BMGLBasel Medical GroupN/A$1.61-9.6%N/AN/A$32.85MN/A0.0036News CoverageCCMConcord Medical Services0.8825 of 5 stars$5.70+3.4%N/A-38.7%$24.88M$52.60M0.00970News Coverage Related Companies and Tools Related Companies KindlyMD Competitors Kindly MD Competitors Quipt Home Medical Competitors Agape ATP Competitors OpGen Competitors P3 Health Partners Competitors Biodesix Competitors Burning Rock Biotech Competitors Basel Medical Group Competitors Concord Medical Services Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRAI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marpai, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marpai With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
